Silicon-containing analogs of camptothecin as anticancer agents (Q48120322)

8 February 2018

http://europepmc.org/abstract/MED/29239010

review article

1 reference

title

Silicon-containing analogs of camptothecin as anticancer agents (English)

1 reference

8 February 2018

http://europepmc.org/abstract/MED/29239010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Viktor P Baryshok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Igor M Lazarev

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

14 December 2017

1 reference

8 February 2018

http://europepmc.org/abstract/MED/29239010

published in

Archiv der Pharmazie - Chemistry in Life Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Camptothecins: a SAR/QSAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

A theoretical study on mechanism of the anticancer drug camptothecin's E-ring-opening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Perspectives on biologically active camptothecin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Cancer therapies utilizing the camptothecins: a review of the in vivo literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Camptothecin. Discovery to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Prodrug analogs of the antitumor alkaloid camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Differential interactions of camptothecin lactone and carboxylate forms with human blood components

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Kinetic and thermodynamic studies of 9-aminocamptothecin hydrolysis at physiological pH in the presence of human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

New hints on the Ph-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Solvent effects on the valence UV-vis absorption spectra of topotecan anticancer drug in aqueous solution at room temperature: a nanoseconds time-scale TD-DFT/MD computational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Increased hydrophobicity and estrogenic activity of simple phenols with silicon and germanium-containing substituents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Semisynthesis of DB-67 and other silatecans from camptothecin by thiol-promoted addition of silyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Catalyst-dependent drug loading of LDI-glycerol polyurethane foams leads to differing controlled release profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

An HPLC assay for the lipophilic camptothecin analog AR‐67 carboxylate and lactone in human whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The comparison of biophysical properties of DB-67 and its ester DB-67-4ABTFA determined by fluorescence spectroscopy methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Hydroxycamptothecin deactivation rates and binding to model membranes and HSA determined by fluorescence spectra analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Determination of hydroxycamptothecin affinities to albumin and membranes by steady-state fluorescence anisotropy measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Quantitative structure–property relationships of camptothecins in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Molecular dynamics simulations and experimental studies of binding and mobility of 7-tert-butyldimethylsilyl-10-hydroxycamptothecin and its 20(S)-4-aminobutyrate ester in DMPC membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Effect of cyclodextrin complexation on the liposome permeability of a model hydrophobic weak Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Incorporation of ionic ligands accelerates drug release from LDI-glycerol polyurethanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Transporter explosion: update on uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Structures and models of transporter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Metabolic pathways of the camptothecin analog AR-67

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

UDP-Glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Validity of the Michaelis-Menten equation--steady-state or reactant stationary assumption: that is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Namitecan: a hydrophilic camptothecin with a promising preclinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Topoisomerase 1 inhibitors and cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

Perspectives in camptothecin development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FARDP.201700297

21 January 2018

Identifiers

DOI

10.1002/ARDP.201700297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29239010%20AND%20SRC:MED&resulttype=core&format=json